



Medivir AB

**Smart, targeted chemotherapy for advanced
liver cancer (HCC)**

April 10, 2024

Jens Lindberg, CEO

MEDIVIR

Important notice

You must read the following before continuing. The following applies to this document and the information provided in this presentation by Medivir AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the “Information”), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions.


The Information does not constitute or form part of, and should not be construed as, an offer of invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a “prospectus” within the meaning of the U.S. Securities Act of 1933, as amended.

The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and will not be updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company’s operations, financial position and earnings. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of the Company’s strategy and its ability to further grow, risks associated with the development and/or approval of the Company’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialize existing and any future products, technology changes and new products in the Company’s potential market and industry, the ability to develop new products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While the Company always intends to express its best judgment when making statements about what it believes will occur in the future, and although the Company bases these statements on assumptions that it believe to be reasonable when made, these forward-looking statements are not a guarantee of its performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

Medivir is a pharmaceutical company developing innovative drugs with a focus on cancer where the unmet medical needs are high





Fostrox

Selectively killing cancer in the liver



Targeted, smart chemotherapy for liver cancer



Wholly owned phase II asset with strong patent protection



Focus on growing, high-value market segment with large unmet need



Potential for accelerated path to approval

Medivir – experience developing drugs to market with a strong track-record in out-licensing

IN-HOUSE PROGRAM – FOSTROX						
PROJECT	DISEASE AREA	PATIENT POPULATION	PRE-CLIN	PH 1	PH 2	PH 3
Fostrox	HCC	Monotherapy POC	Completed	Completed		
		Fostrox + Lenvima	Completed	Completed	Ongoing	Planned
		Fostrox + Keytruda	Completed	Completed		


- Fostrox – fully developed in-house

PARTNERED PROGRAMS							
PROJECT	PARTNER	DISEASE AREA	PRE-CLIN	PH 1	PH 2	PH 3	MARKET
Xerclear	GSK	Herpes	Completed	Completed	Completed	Completed	Completed
Olysio	J&J	Hepatitis C	Completed	Completed	Completed	Completed	Completed
Birinapant	IGM	Solid tumors	Completed	Completed			
TNG348	Tango	Cancer	Completed	Ongoing			
USP-7	Ubiquigent	Cancer	Completed				
MET-X	INFEX	Infection	Completed	Ongoing			

- 2 Medivir compounds developed to market
- 4 out-licensed programs, 2 in clinical trials

Completed
Ongoing
Planned

Targeted treatment approach critical in liver cancer




- ~80% have underlying liver disease, negatively impacting ability to tolerate systemic anti-cancer treatments^{1,2}
- Tumor growth in HCC is unique as it primarily occurs locally in the liver¹

¹ Senthilnathan et al., Hepatology, 2012 May; 55(5): 1432-1442


² Llovet et al., Nature Reviews Gastroenterology & Hepatology, Vol 20, Aug 2023, 487-503

Only 10% of second line patients respond to current therapies




¹Based on data from previous 2L phase 3 HCC studies with Stivarga, Cyramza & Cabometyx and investigator initiated prospective & retrospective 2L studies with lenvatinib

Fostrox – a smart chemotherapy targeting cancer in the liver



Global phase 1b/2a study with fostrox + Lenvima (TKI)




Key study features

- Advanced HCC with generous inclusion criteria, including 2L & 3L patients
- Evaluates potential for synergy between fostrox and Lenvima
- Open-label, single arm, 21 pts
- Final read-out anticipated H2 2024

Significantly higher response rate than current 2L treatments^{1,2}

Best percentage change in target lesion size




¹Local review (All 21 patients data cut-off February 14, 2024) RECIST 1.1


²Based on data from previous 2L phase 3 HCC studies with Stivarga, Cyramza & Cabometyx and investigator initiated prospective & retrospective 2L studies with lenvatinib

Fostrox extends TTP compared to current 2L treatments¹

Time to progression (TTP)




2L TTP/PFS benchmark (mts)²



¹Local review (All 21 patients data cut-off February 14, 2024), RECIST 1,1

²Based on data from previous 2L phase 3 HCC studies with Stivarga, Cyramza & Cabometyx and investigator initiated prospective & retrospective 2L studies with lenvatinib

A majority of patients tolerate full dose of fostrox long-term¹



Second line HCC market worth over USD 2.5 billion by 2030

Large unmet need in fast growing population

3rd

leading cause of cancer death worldwide¹


+122%

HCC expected to increase +122% in the US and +82% in China² by 2030, caused by fatty liver disease

No

approved treatments in second line post IO-combo

Total market potential > USD 2.5bn by 2030 & growing³




¹Rumguy et al. Journal of Hepatology 2022

²Huang et al., Nature Reviews, Gastroenterology & Hepatology, Vol 18, 2021


³GlobalData 2021 and internal analysis

Next step – scaled up global phase 2b to provide opportunity for accelerated approval



★ Accelerated approval ★ Full approval


Fostrox – making good progress preparing for phase 2b



Activity delivered ✓

Fostrox – potential to improve second line HCC therapy

Smart chemotherapy



selectively killing cancer cells in the liver

Improving outcomes

2x

response rate & time to progression

First-to-market opportunity

\$2.5bn

market in patients with no approved treatments



Thank You!